![](https://endpts.com/wp-content/uploads/2023/03/David-Bejker-Affibody-tile.jpg)
David Bejker, Affibody CEO
Chiesi puts down $200M+ to collaborate with Affibody for respiratory diseases
The Italian drug developer Chiesi will be looking to drop nine figures to develop several treatments for respiratory diseases in a deal with Swedish biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.